TXG Stock Jumps As AI Deal And Legal Win Shift Momentum
10x Genomics Inc. (TXG) stock rose 12.23% on September 24, 2026, driven by investor optimism over AI partnerships and a legal win. The company's stock has increased over 35% in under a month, reaching $84.91. TXG reported $151M in quarterly revenue with a 70% gross margin but remains unprofitable. Analysts have mixed views, with targets around $70, while traders focus on momentum and future growth potential.
How this was made
The 30-second read
Why it matters
The combination of a patent win and AI partnership provides a narrative catalyst that can sustain short‑term price gains, but fundamentals remain weak.
Market read
TXG's sharp intraday rally driven by fresh legal and AI news offers a short‑term trading opportunity, while sector sentiment may benefit peers.
What to watch
Insider sales and flat single‑cell revenue forecasts may limit upside despite the hype.
Background
10x Genomics (TXG) is a high‑growth biotech supplying spatial and single‑cell genomics platforms.
Ticker impact
TXG jumped 12% intraday after a jury patent win against Qiagen and an AI partnership with Lunit, driving strong short‑term momentum.
Potential continuation of the uptrend with further 5‑10% gains if momentum holds.
Both catalysts are fresh, material to the business, and the stock is already in a strong technical uptrend.
Market effects
Strengthens the spatial biology and AI‑in‑healthcare sectors, potentially lifting peers.
U.S. biotech and AI‑focused investors may see increased buying pressure.
Highlights the growing importance of AI integration in life‑science tools worldwide.
Counterpoint
The company remains loss‑making with high cash burn; a pullback could occur if earnings disappoint.
Key entities
- company10x Genomics Inc.
Subject of the article; ticker TXG.
- competitorQiagen / Parse Biosciences
Defendant in the patent lawsuit.
- partnerLunit
AI pathology engine integrated into TXG platforms.
